知镜 Cognispect · 医学文献与研究工作台

Effects of Danhong Injection on 90-Day Functional Outcome in Acute Ischemic Stroke: An Adaptive, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Trial.

Liu J, Wang Y, Chen B, Lu J, Chen L, Guan S, Shi Y, Liu W, Yu Y, Li B, Dang H, Zhu X, Teng F, Liu X, Zhou N, Chen Q, Shen C, Zhu L, Wang Y, Zhao X, Wang Z, Danhong‐Stroke Trial Investigators.
MedComm · 2026-11-08 · PMID 43001080

文献摘要

Therapeutic options for neurological recovery remain limited in acute ischemic stroke (AIS) patients ineligible for thrombolysis, and while multitarget drugs like Danhong injection ( DHI ) demonstrate efficacy, their polypharmacological mechanisms remain understood. In this trial including 1505 thrombolysis-ineligible AIS patients with anterior-circulation and blood stasis syndrome (NCT01677208), 14-day treatment with DHI ( n = 1002) versus placebo ( n = 503) demonstrated superior 90-day outcomes (modified Rankin scale [mRS] score ≤1: 64.57 vs. 59.24%; adjusted odds ratio 1.43, 95%CI 1.10-1.86, p = 0.007), particularly in females and hypertensive patients, and no significant between-group differences in any serious adverse events (all p > 0.05). In the exploratory RNA-sequencing substudy of 39 patients (24 DHI , 15 placebo), we identified 19 differentially expressed modules, including two paired targeted modules " HBG2 " and " TMEM108 ," whose topological features showed opposite correlations with the primary clinical outcome (δmRS at Day 90). Furthermore, a combination effect model was introduced to describe the time-dependent joint association of these modules with outcome (combination effect score: -0.729 at Day 0, 0.227 at Day 14, and 1 at Day 90). These findings demonstrate DHI may be a favorable treatment option for thrombolysis-ineligible AIS patients and provide a proposed analytical framework for future, independently validated studies of multitarget drug actions in complex diseases.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。